Tag: <span>Leukemia</span>

Home / Leukemia
Post

Researchers discover compound that fights leukemia and lymphoma

by University of Texas at El Paso Renato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator on a project that identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy....

Leukemia: Artificial intelligence provides support in diagnostics
Post

Leukemia: Artificial intelligence provides support in diagnostics

by Kathrin Kottke, University of Münster Credit: Blood Advances (2023). DOI: 10.1182/bloodadvances.2023011076Decisions on treatment for patients with acute myeloid leukemia (AML)—a highly aggressive form of leukemia—are based, among other things, on a series of certain genetic features of the disease; but at the time when a diagnosis is made, this information is not available. Evidence of...

Allogeneic HCT after primary induction failure beneficial in leukemia
Post

Allogeneic HCT after primary induction failure beneficial in leukemia

by Elana Gotkine For patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term survival benefit, according to a study published online Dec. 10 in the Blood Cancer Journal. Miriam Mozaffari Jovein, M.D., from the University of Freiburg in Germany, and colleagues retrospectively assessed long-term...

Finding and targeting a tumor’s sweet spot to eradicate aggressive form of leukemia
Post

Finding and targeting a tumor’s sweet spot to eradicate aggressive form of leukemia

by University of Birmingham Credit: Cell Reports (2023). DOI: 10.1016/j.celrep.2023.113568 A highly aggressive common form of leukemia which is activated by mutations in signaling molecules is maintained by a web of regulatory proteins downstream of these signals. New research published in Cell Reports shows that a complex network of interacting genes activated by this altered signaling...

Fighting leukemia with therapeutic RNA
Post

Fighting leukemia with therapeutic RNA

by Goethe University Frankfurt am Main AML xenografts are susceptible to transient LNP/miR-193b treatment in vitro. A The absolute number of human AML PDX cells after treatment with single dose of 4 µg/ml LNPs. B Percentage of apoptotic cells (Annexin V+) on day 2 post treatment. A, B Data are represented as the mean ± standard deviation of three...

Post

How Targeted Drugs Can Vanquish a Virulent Leukemia

Randy Dotinga For patients with acute myeloid leukemia (AML), especially those who are older or have relapsed/refractory disease, standard chemotherapy treatments often fail to change their poor clinical trajectories. These days, however, a new era of targeted therapy is improving prognoses somewhat — and raising hopes that even bigger advancements are on the horizon. “We...

Discovery unlocks potential new arsenal to target leukemia and other cancers
Post

Discovery unlocks potential new arsenal to target leukemia and other cancers

by QIMR Berghofer Integrative analysis of samples from patients with AML. a, Unsupervised hierarchical clustering analysis on the expression of 300 transcripts with the greatest variance-to-mean ratios among 30 individual AMLs from our repository that can successfully generate AML PDX. MLD, multi-lineage dysplasia; MDS, myelodysplastic syndromes; MLL, mixed-lineage leukemia; NOS, not otherwise specified. b, Key...

Scientists unravel how TET2 gene deficiency fuels development of acute myeloid leukemia
Post

Scientists unravel how TET2 gene deficiency fuels development of acute myeloid leukemia

by City of Hope National Medical Center The return (i.e., homing) of leukemia stem cells (green) to the bone marrow microenvironment/niche (red) is substantially enhanced by low levels of TET2, at right, compared to the wild-type version of the gene. Credit: Jianjun Chen Laboratory/City of Hope Scientists at City of Hope, one of the largest cancer...

Study finds increased MDS/leukemia risks for survivors of common lymphoid neoplasms
Post

Study finds increased MDS/leukemia risks for survivors of common lymphoid neoplasms

by Elana Gotkine Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published in the July issue of e ClinicalMedicine. Lindsay M. Morton, Ph.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues identified...

Leukemia spread fueled by messenger particles, shows study
Post

Leukemia spread fueled by messenger particles, shows study

by King Abdullah University of Science and Technology Mass spectrometry analysis reveals HSPCs-derived exosomes are enriched in proteins involved in adhesion and migration. Proteomics analysis of the cargo was performed to uncover putative functions of the isolated exosomes. The KEGG pathways and the Biological Processes from Gene Ontology analysis that were enriched in the KG1a (pink)...